← Back to Clinical Trials
Recruiting NCT06028165

NCT06028165 CABG Based on CT-FFR Versus Conventional Coronary Angiography

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06028165
Status Recruiting
Phase
Sponsor Myongji Hospital
Condition Coronary Artery Disease
Study Type INTERVENTIONAL
Enrollment 96 participants
Start Date 2023-10-20
Primary Completion 2024-10-01

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Coronary artery bypass grafting based on conventional coronary angiographyCoronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 96 participants in total. It began in 2023-10-20 with a primary completion date of 2024-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aims of study are (1) to compare early and 1-year graft patency rates in patients who underwent coronary artery bypass grafting (CABG) based on conventional coronary angiography(CAG) versus cardiac computed tomography(CT)-derived fractional flow reserve(FFR), and (2) to demonstrate difference in clinical outcomes between the 2 groups.

Eligibility Criteria

Inclusion Criteria: * age equal or more than 40 * age equal or less than 80 * patients who undergo coronary artery bypass grafting due to multi-vessel coronary artery disease * patients who agree to the enrollment Exclusion Criteria: * Patients with heart failure (left ventricular ejection fraction \< 25%) * patients who have intractable ventricular arrhythmia * patients who has been treated for cancer * patients who has infectious disease * patients who are planned to undergo combined cardiac surgery * patients who has medical co-morbidity with expected survival less than 1 year * patients with a history of previous cardiac surgery * Patients with chronic renal failure requiring dialysis * patients who undergo emergency operation

Contact & Investigator

Central Contact

Min-Seok Kim, MD, PhD, MSc

✉ minseok.kim.md.phd@gmail.com

📞 82-10-8482-0380

Principal Investigator

Min-Seok Kim, MD, PhD, MSc

STUDY CHAIR

Cardiovascular Center, Myongji Hospital

Frequently Asked Questions

Who can join the NCT06028165 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06028165 currently recruiting?

Yes, NCT06028165 is actively recruiting participants. Contact the research team at minseok.kim.md.phd@gmail.com for enrollment information.

Where is the NCT06028165 trial being conducted?

This trial is being conducted at Goyang-si, South Korea.

Who is sponsoring the NCT06028165 clinical trial?

NCT06028165 is sponsored by Myongji Hospital. The principal investigator is Min-Seok Kim, MD, PhD, MSc at Cardiovascular Center, Myongji Hospital. The trial plans to enroll 96 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology